Second Amendment to the Loan Agreement, dated February 15, 2022, by and among MoonLake Immunotherapeutics AG and the Lenders named therein

Exhibit 10.30

Certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.

Amendment to the Loan Agreement dated as of October 15, 2021, as amended

of February 15, 2022

between

44 Montgomery Street, 40^th Floor

San Francisco, CA 94104, USA

[***]

(hereinafter “Lender 1”)

44 Montgomery Street, 40^th Floor

San Francisco, CA 94104, USA

[***]

(hereinafter “Lender 2”)

PO Box 309 Ugland House, Grand Cayman

KY1-1104, Cayman Islands

[***]

(hereinafter “Lender 3”)

(each a “Lender” and collectively the “Lenders”)

and

Dorfstrasse 29

6300 Zug, Switzerland

(hereinafter the “Borrower”)

(the Lenders, the Borrower each a “Party” and collectively the “Parties”)

TAble of contents

Now, therefore, the Parties agree as follows:

Capitalized terms used in this Amendment Agreement shall have the respective meanings as set forth in the Loan Agreement.

The Parties agree to replace Section 6 of the Loan Agreement in its entirety with the following section:

The Loans granted hereunder are granted for a fixed period of time until the earlier of (i) as soon as practicable after the Transaction Closing, but no later than two (2) business days, and (ii) June 30, 2022 (the “Maturity Date”).

The Loans may be repaid in whole or in part by the Borrower at any time on or prior to the Maturity Date.

The existing provisions of the Loan Agreement shall, except as amended in this Amendment Agreement, continue in full force and effect, and shall be read and construed as one document together with this Amendment Agreement.

This Amendment Agreement shall enter into force upon signature by all Parties and shall automatically end upon termination of the Loan Agreement.

Section 12 of the Loan Agreement shall apply to this Amendment Agreement.

This Amendment Agreement shall in all respects be governed by and construed in accordance with Swiss law under the exclusion of its private international law provisions and international treaties.

Any dispute, controversy or claim arising out of, or in relation to, this con-tract, including the validity, invalidity, breach, or termination thereof, shall be subject to the exclusive jurisdiction of the courts of Zug, Canton of Zug, Switzerland.

[signature page to follow]

Borrower

MoonLake Immunotherapeutics AG

5